T-cell Dynamics After High-dose Chemotherapy in Adults: Elucidation of the Elusive CD8+ Subset Reveals Multiple Homeostatic T-cell Compartments with Distinct Implications for Immune Competence
Overview
Authors
Affiliations
Recovery of total T cell numbers after in vivo T-cell depletion in humans is accompanied by complex perturbation within the CD8+ subset. We aimed to elucidate the reconstitution of CD8+ T cells by separate analysis of putative naïve CD95- CD28+, memory CD95+ CD28+ and CD28- T cell compartments after acute maximal depletion by high-dose chemotherapy (HD-ChT) in women with high-risk breast cancer. We found that recovery of putative naïve CD8+ CD95- CD28+ and CD4+ CD95- CD28+ T cells, was compatible with a thymus-dependent regenerative pathway since their recovery was slow and time-dependent, their values were tightly related to each other, and their reconstitution patterns were inversely related to age. By analysing non-naïve T cells, a striking diversion between putative memory T cells and CD28- T cells was found. These latter increased early well beyond normal values, thus playing a pivotal role in total T-cell homeostasis, and contributed to reduce the CD4 : CD8 ratio. In contrast, putative memory T cells returned to values not significantly different from those seen in patients at diagnosis, indicating that this compartment may recover after HD-ChT. At 3-5 years after treatment, naïve T cells persisted at low levels, with expansion of CD28- T cells, suggesting that such alterations may extend further. These findings indicate that CD28- T cells were responsible for 'blind' T-cell homeostasis, but support the notion that memory and naïve T cells are regulated separately. Given their distinct dynamics, quantitative evaluation of T-cell pools in patients undergoing chemotherapy should take into account separate analysis of naïve, memory and CD28- T cells.
Sustained lymphocyte decreases after treatment for early breast cancer.
Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen S, Savas P NPJ Breast Cancer. 2024; 10(1):94.
PMID: 39433772 PMC: 11493948. DOI: 10.1038/s41523-024-00698-4.
Generation of autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy.
Maneechai K, Khopanlert W, Noiperm P, Udomsak P, Viboonjuntra P, Julamanee J Heliyon. 2024; 10(19):e38447.
PMID: 39398019 PMC: 11467635. DOI: 10.1016/j.heliyon.2024.e38447.
Kientega T, Marcoux S, Bourbonnais J, Montpetit J, Caru M, B Cardin G Blood Cancer J. 2024; 14(1):96.
PMID: 38871704 PMC: 11176394. DOI: 10.1038/s41408-024-01071-1.
Chauhan S, Dunn C, Andresen N, Rossevold A, Skorstad G, Sike A NPJ Breast Cancer. 2024; 10(1):30.
PMID: 38653982 PMC: 11039627. DOI: 10.1038/s41523-024-00638-2.
Heiser R, Cao A, Zeng W, Ulrich M, Younan P, Anderson M Mol Cancer Ther. 2023; 23(1):68-83.
PMID: 37775098 PMC: 10762337. DOI: 10.1158/1535-7163.MCT-23-0118.